ArticleAdvanced therapeutics2024
Pharmacokinetics and Biodistribution of Phages and their Current Applications in Antimicrobial Therapy.
Article in Advanced therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Post-Microbial Therapeutics for the Next Generation of Medicine.MicrobiologyOpen · 2026Review
- Unlocking the potential of bacteriophage-based therapeutic gene delivery in hepatocellular carcinoma.Journal of the Egyptian National Cancer Institute · 2026Review
- Comparative Study of Bacteriophage Pharmacokinetics by Different Enteral Administration Routes.Methods and protocols · 2026Article
- Extensive screening of ten bacteriophage cocktails revealed an optimal combination with potent therapeutic activity against Acinetobacter baumannii.Scientific reports · 2026Article
- Bacteriophages as Therapeutic Agents for Pulmonary Infections: From Biological Principles to Clinical Applications.Pharmaceutics · 2026Review
- Bacteriophage-Based Control of Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Phage-Based Approaches to ChronicAntibiotics (Basel, Switzerland) · 2026Review
- Bacteriophage Therapy: Overcoming Antimicrobial Resistance Through Advanced Delivery Methods.Molecules (Basel, Switzerland) · 2026Review
- Whole-body distribution of threeAntimicrobial agents and chemotherapy · 2026Article
- Bacteriophage pharmacodynamics studied in anJAC-antimicrobial resistance · 2025Article
- A Comprehensive Review of the Application of Bacteriophages Against Enteric Bacterial Infection in Poultry: Current Status, Challenges, and Future Prospects.Antibiotics (Basel, Switzerland) · 2025Review
- An ultrasensitive and modular platform to detect Siglec ligands and control immune cell function.Science advances · 2025Article
- Therapeutic application of a jumbo bacteriophage against metallo-β-lactamase producing Pseudomonas aeruginosa clinical isolates.Journal of biomedical science · 2025Article
- Bacteriophage therapy for multidrug-resistant infections: current technologies and therapeutic approaches.The Journal of clinical investigation · 2025Review
- Evaluation of host immune responses to Mycobacteriophage Fionnbharth by route of delivery.Virology journal · 2025Article
- Bacteriophages: A Challenge for Antimicrobial Therapy.Microorganisms · 2025Review
- Advancing Phage Therapy: A Comprehensive Review of the Safety, Efficacy, and Future Prospects for the Targeted Treatment of Bacterial Infections.Infectious disease reports · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Antimicrobial resistance remains a critical global health concern, necessitating the investigation of alternative therapeutic approaches. With the diminished efficacy of conventional small molecule drugs due to the emergence of highly resilient bacterial strains, there is growing interest in the potential for alternative therapeutic modalities. As naturally occurring viruses of bacteria, bacteriophage (or phage) are being re-envisioned as a platform to engineer properties that can be tailored to target specific bacterial strains and employ diverse antibacterial mechanisms. However, limited understanding of key pharmacological properties of phage is a major challenge to translating its use from preclinical to clinical settings. Here, we review modern advancements in phage-based antimicrobial therapy and discuss the in vivo pharmacokinetics and biodistribution of phage, addressing critical challenges in their application that must be overcome for successful clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.